Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Moodys
Mallinckrodt
Dow
Harvard Business School

Last Updated: June 27, 2022

Patent: 10,001,483


✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,001,483
Title:Methods for the treatment of Kaposi\'s sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
Abstract: Provided herein are uses of gene and protein biomarkers as a predictor of clinical sensitivity of Kaposi\'s sarcoma (KS) or Kaposi\'s sarcoma-associated herpesvirus (KSHV) induced lymphoma and patient response to treatment with an immunomodulatory compound. Further provided herein are methods for the treatment or management of Kaposi\'s sarcoma or KSHV-induced lymphoma with an immunomodulatory compound, alone or in combination with doxorubicin.
Inventor(s): Yarchoan; Robert (Bethesda, MD), Zeldis; Jerome B. (Princeton, NJ), Polizzotto; Mark N. (New South Wales, AU), Davis; David A. (Bethesda, MD), Sereti; Irini (Washington, DC), Uldrick; Thomas S. (Washington, DC), Whitby; Denise (Frederick, MD), Khetani; Vikram (Short Hills, NJ)
Assignee: Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)
Application Number:15/192,819
Patent Claims:see list of patent claims

Details for Patent 10,001,483

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab For Injection 125514 09/04/2014 See Plans and Pricing 2035-06-26
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab Injection 125514 01/15/2015 See Plans and Pricing 2035-06-26
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 12/22/2014 See Plans and Pricing 2035-06-26
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 10/04/2017 See Plans and Pricing 2035-06-26
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 08/27/2021 See Plans and Pricing 2035-06-26
Genentech, Inc. TECENTRIQ atezolizumab Injection 761034 05/18/2016 See Plans and Pricing 2035-06-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Medtronic
Colorcon
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.